Production (Stage)
Heron Therapeutics, Inc.
HRTX
$2.12
$0.020.95%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 148.52M | 144.29M | 137.74M | 136.36M | 132.10M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 148.52M | 144.29M | 137.74M | 136.36M | 132.10M |
| Cost of Revenue | 53.02M | 55.33M | 55.61M | 69.18M | 87.60M |
| Gross Profit | 95.50M | 88.95M | 82.13M | 67.18M | 44.50M |
| SG&A Expenses | 99.08M | 100.48M | 90.45M | 95.97M | 109.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 152.09M | 155.81M | 146.06M | 165.15M | 196.85M |
| Operating Income | -3.58M | -11.53M | -8.32M | -28.79M | -64.75M |
| Income Before Tax | -7.79M | -13.58M | -27.97M | -48.13M | -80.95M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.79 | -13.58 | -27.97 | -48.13 | -80.95 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.79M | -13.58M | -27.97M | -48.13M | -80.95M |
| EBIT | -3.58M | -11.53M | -8.32M | -28.79M | -64.75M |
| EBITDA | -1.22M | -9.04M | -5.70M | -26.02M | -61.88M |
| EPS Basic | -0.05 | -0.09 | -0.18 | -0.32 | -0.61 |
| Normalized Basic EPS | -0.02 | -0.05 | -0.04 | -0.13 | -0.31 |
| EPS Diluted | -0.06 | -0.09 | -0.18 | -0.32 | -0.61 |
| Normalized Diluted EPS | -0.03 | -0.05 | -0.04 | -0.13 | -0.31 |
| Average Basic Shares Outstanding | 611.78M | 609.49M | 609.53M | 601.69M | 569.11M |
| Average Diluted Shares Outstanding | 655.21M | 609.49M | 609.53M | 601.69M | 569.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |